---
document_datetime: 2025-06-02 19:08:24
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/corbilta-previously-levodopa-carbidopa-entacapone-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: corbilta-previously-levodopa-carbidopa-entacapone-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1072403
conversion_datetime: 2025-12-21 23:27:39.252474
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Corbilta

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,please alsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc. Article 61(3) - | 02/06/2025                          |                                          | PL                              |           |

1Notifications areissuedfortypeIvariations andArticle61(3)notifications(unlesspartofagroupincludinga typeIIvariationorextensionapplicationoraworksharingapplication).Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),Annex II,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annex II, labelling,package leaflet).The CDisissuedwithintwomonthsof theopinionforvariationsfallingunderthescopeofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000275731                    | Update of the package leaflet with the additionofcontactdetailsoflocal representatives.                                                                                 |            |     |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation typeIA/ EMA/VR/0000258401 | B.III.1.aEuropeanPharmacopoeial Certificate ofSuitability to therelevantPh. Eur.Monograph-B.III.1.a.2 Updated certificatefrom an already approved manufacturer-Accepted | 10/04/2025 | N/A |